Huntington National Bank’s Avadel Pharmaceuticals AVDL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $16 | Hold |
1
| – | – | ﹤0.01% | 3742 |
|
|
2026
Q1 | $16 | Hold |
1
| – | – | ﹤0.01% | 3571 |
|
|
2025
Q4 | $16 | Hold |
1
| – | – | ﹤0.01% | 3495 |
|
|
2025
Q3 | $16 | Hold |
1
| – | – | ﹤0.01% | 3532 |
|
|
2025
Q2 | $16 | Hold |
1
| – | – | ﹤0.01% | 3539 |
|
|
2025
Q1 | $16 | Hold |
1
| – | – | ﹤0.01% | 3565 |
|
|
2024
Q4 | $16 | Hold |
1
| – | – | ﹤0.01% | 3573 |
|
|
2024
Q3 | $16 | Hold |
1
| – | – | ﹤0.01% | 3569 |
|
|
2024
Q2 | $16 | Hold |
1
| – | – | ﹤0.01% | 3524 |
|
|
2024
Q1 | $17 | Hold |
1
| – | – | ﹤0.01% | 3362 |
|
|
2023
Q4 | $14 | Hold |
1
| – | – | ﹤0.01% | 3333 |
|
|
2023
Q3 | $10 | Hold |
1
| – | – | ﹤0.01% | 3415 |
|
|
2023
Q2 | $16 | Hold |
1
| – | – | ﹤0.01% | 3237 |
|
|
2023
Q1 | $9 | Hold |
1
| – | – | ﹤0.01% | 3272 |
|
|
2022
Q4 | $7 | Hold |
1
| – | – | ﹤0.01% | 3183 |
|
|
2022
Q3 | $0 | Hold |
1
| – | – | ﹤0.01% | 2004 |
|
|
2022
Q2 | $0 | Hold |
1
| – | – | ﹤0.01% | 2035 |
|
|
2022
Q1 | $0 | Hold |
1
| – | – | ﹤0.01% | 2040 |
|
|
2021
Q4 | $0 | Buy |
+1
| New | +$9 | ﹤0.01% | 2016 |
|
|
2015
Q4 | – | Sell |
-1,274
| Closed | -$21K | – | 1642 |
|
|
2015
Q3 | $21K | Sell |
1,274
-652
| -34% | -$14.4K | ﹤0.01% | 1246 |
|
|
2015
Q2 | $41K | Buy |
+1,926
| New | +$34.5K | ﹤0.01% | 1161 |
|
Huntington National Bank's AVDL Position: Q2 2026 in Review
Huntington National Bank held its Avadel Pharmaceuticals (AVDL) position steady in Q2 2026 at 1 share worth $16. The position accounts for ﹤0.01% of the portfolio, ranked #3742.
Huntington National Bank first reported a position in AVDL in Q2 2015 and has held it in 21 quarters since. The position peaked at $41K in Q2 2015. 1 fund tracked by Wall St. Rank holds AVDL as of Q2 2026.
- Huntington National Bank held 1 share of Avadel Pharmaceuticals worth $16 as of Q2 2026.
- Huntington National Bank left its Avadel Pharmaceuticals share count unchanged in Q2 2026.
- Avadel Pharmaceuticals made up ﹤0.01% of Huntington National Bank's portfolio in Q2 2026, its #3742 holding.
- Huntington National Bank first reported a position in Avadel Pharmaceuticals in Q2 2015 and has held it in 21 quarters since.
- Huntington National Bank's Avadel Pharmaceuticals position peaked at $41K in Q2 2015.
- 1 fund tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q2 2026.
Based on Huntington National Bank's 13F filing for Q2 2026, filed 13 Aug 2026.